BELLEVUE, Wash. and SEOUL, South Korea, Nov. 16, 2023 /PRNewswire/ -- Bellevue Life Sciences Acquisition Corp. (Nasdaq: BLAC), a publicly traded special purpose acquisition company ('BLAC'), and OSR Holdings Co., Ltd. ('OSR Holdings'), a global healthcare holding company, announced today that they have entered into a business combination agreement.

BELLEVUE，Wash。和韩国首尔，2023年11月16日/PRNewswire/-BELLEVUE生命科学收购公司（纳斯达克股票代码：BLAC），一家上市的特种收购公司（'BLAC'）和OSR Holdings全球医疗保健控股公司有限公司（'OSR Holdings'）今天宣布他们已签订业务组合协议。

Upon closing of the transaction, outstanding shares of OSR Holdings held by certain of the holders of OSR Holdings' common stock will be exchanged for newly issued shares of BLAC common stock. Following the closing, BLAC will own at least 60% of the outstanding shares of OSR Holdings (and have the right to acquire the remainder of the shares on or after January 1, 2025 or 2026 or in connection with a change in control of BLAC).  Concurrent with the closing of the business combination, BLAC intends to change its name to OSR Biosciences, Inc.

交易结束后，OSR Holdings普通股某些持有人持有的OSR Holdings已发行股份将换成新发行的BLAC普通股股份。结束后，BLAC将拥有至少60%的OSR持有已发行股份（并有权在2025年或2026年1月1日或之后或与BLAC控制权变更相关时收购其余股份）。在业务组合结束的同时，BLAC打算将其名称更改为OSR Biosciences，Inc。

and have its common stock and warrants be listed on Nasdaq Capital Market under new ticker symbols..

并拥有其普通股和认股权证，在纳斯达克资本市场上以新的票务符号上市。。

Founded in 2019, OSR Holdings is a global healthcare holding company from South Korea with wholly owned operating subsidiaries in the biopharmaceutical and medical device sectors. Current subsidiaries include: 1) Vaximm that develops immunotherapy for cancer treatment, 2) Darnatein that develops disease-modifying osteoarthritis drug (DMOAD), and 3) RMC that distributes medical device for the treatment of neurovascular and other diseases.

OSR Holdings成立于2019年，是一家来自韩国的全球医疗保健控股公司，拥有生物制药和医疗器械行业的国有经营子公司。目前的子公司包括：1）开发用于癌症治疗的免疫疗法的Vaximm，2）开发改善疾病的骨关节炎药物（DMOAD）的Darnatein，以及3）分发用于治疗神经血管和其他疾病的医疗器械的RMC。

On July 7, 2023, OSR Holdings signed a non-binding letter of intent for a proposed acquisition of Landmark BioVentures AG, a Swiss company that operates through four different biotech ventures in France with therapeutic focuses on oncology and immunology..

2023年7月7日，OSR Holdings签署了一份无约束力的意向书，拟收购Landmark BioVentures AG，该公司通过法国的四家不同生物技术企业运营，专注于肿瘤学和免疫学。。

Vaximm is a Basel, Switzerland-based drug development company developing T-cell immunotherapies for cancer patients with its proprietary plug and play platform technology for oral administration. Vaximm was established as a spin-off from the German pharmaceutical company Merck KGaA. Currently, Zaki Sellam, a bio-healthcare business development specialist, serves as the CEO..

Vaximm是一家位于瑞士巴塞尔的药物开发公司，通过其专有的口服即插即用平台技术为癌症患者开发T细胞免疫疗法。Vaximm成立是德国制药公司Merck KGaA的分拆产品。目前，生物医疗保健业务开发专家Zaki Sellam担任首席执行官。。

Darnatein is a Incheon, South Korea-based drug development company founded by Dr. Choi Seung-hyun, a founding research member of the Structural Biology Laboratory at Salk Institute, with a focus on developing treatment for osteoarthritis. Darnatein aims to address the unmet medical need for the current osteoarthritis treatment, which is often limited to palliative or anti-inflammatory effects, by utilizing its platform technology designed to regenerate bone and cartilage..

Darnatein是一家位于韩国仁川的药物开发公司，由索尔克研究所结构生物学实验室的创始研究成员Choi-Seung-hyun博士创立，专注于开发骨关节炎治疗。Darnatein旨在通过利用其旨在再生骨骼和软骨的平台技术来解决当前骨关节炎治疗的未满足的医疗需求，这种治疗通常局限于姑息或抗炎作用。。

RMC is a South Korean distribution agent of global medical device manufacturers including Penumbra, Asahi-Intec, Microport, and Zylox-Tonbridge. RMC is led by Chan Kyu Park, a specialist in the field of vascular neurology. Mr. Park was also a founding member of Hutem Co., Ltd., a company that was acquired by a Kosdaq-listed company Hugel Co., Ltd.

RMC是全球医疗器械制造商的韩国分销代理商，包括Penumbra，Asahi Intec，Microport和Zylox Tonbridge。RMC由血管神经病学领域的专家Chan-Kyu Park领导。Park先生也是Hutem Co.，Ltd。的创始成员，Hutem Co.，Ltd。是一家被Kosdaq上市公司Hugel Co.，Ltd收购的公司。

in 2015..

在2015年。。

'I would like to express my sincere gratitude to our shareholders who have shown unwavering trust and support to OSR Holdings that led us to this accomplishment.' said Sung Jae Yu, Chief Operating Officer of OSR Holdings. 'Through our business combination with BLAC, we plan to further expand our portfolio by acquiring prospective healthcare companies with innovative technology designed to better position ourselves as a global leader in the healthcare industry'..

“我衷心感谢我们的股东，他们对OSR控股公司表示了坚定的信任和支持，这使我们取得了这一成就。”OSR Holdings首席运营官Sung-Jae Yu说通过与BLAC的业务组合，我们计划通过收购具有创新技术的未来医疗保健公司来进一步扩大我们的投资组合，旨在更好地将自己定位为医疗保健行业的全球领导者。。

'OSR Holdings possesses innovative technologies that enable the developments of therapies for various diseases,' said Dr. Steven G. Reed, Chairman of the Board of BLAC. 'The signing of the business combination agreement marks a significant milestone for OSR Holdings and is designed to enhance its presence to newer heights in the global healthcare industry..

BLAC董事会主席Steven G.Reed博士说：“OSR Holdings拥有创新技术，可以开发各种疾病的治疗方法。”签署业务组合协议标志着OSR持有的一个重要里程碑，旨在将其在全球医疗保健行业的地位提升到新的高度。。

About OSR Holdings

关于OSR持有量

OSR Holdings is a global healthcare company that leverages its international network of companies and development partners in the Europe, South Korea and US seeking to develop and license its pipeline of innovative biomedical therapies based on proprietary platform technologies, with the goal of addressing unmet medical needs.

OSR Holdings是一家全球医疗保健公司，利用其在欧洲，韩国和美国的国际公司和开发合作伙伴网络，寻求开发和许可基于专有平台技术的创新生物医学疗法管道，目标是解决未满足的医疗需求。

OSR Holdings currently wholly-owns three operating subsidiaries in Switzerland and South Korea, two of which are focused on developing therapeutic drugs in the areas of oncology and osteoarthritis, and the third is a distributor of medical devices for the treatment of neurovascular and other diseases.

OSR Holdings目前在瑞士和韩国完全拥有三家经营子公司，其中两家专注于开发肿瘤和骨关节炎领域的治疗药物，第三家是治疗神经血管和其他疾病的医疗器械分销商。

For more information, visit www.osr-holdings.com..

欲了解更多信息，请访问www.osr-holdings.com。。

About Bellevue Life Sciences Acquisition Corp

关于贝尔维尤生命科学收购公司

BLAC is a special purpose acquisition company that completed its initial public offering in February 2023. BLAC's sponsor, Bellevue Global Life Sciences Investors LLC, is an affiliate of Bellevue Capital Management, LLC, a Bellevue, Washington-based global healthcare investment firm. BLAC's sponsor management team has decades of combined experience in healthcare investing and extensive experience in mergers and acquisitions, investment banking, and investment management including within the healthcare sector.

BLAC是一家特种收购公司，于2023年2月完成首次公开发行。BLAC的赞助商Bellevue Global Life Sciences Investors LLC是位于华盛顿州Bellevue的全球医疗保健投资公司Bellevue Capital Management，LLC的子公司。BLAC的赞助商管理团队在医疗保健投资方面拥有数十年的综合经验，在兼并，投资银行和包括医疗保健部门在内的投资管理方面拥有丰富的经验。

For more information, visit www.bellevuespac.com..

For more information, visit www.bellevuespac.com..

Additional Information and Where to Find It

其他信息以及在哪里找到它

BLAC will prepare a proxy statement/prospectus (the 'BLAC proxy statement/prospectus') to be filed with the U.S. Securities and Exchange Commission (the 'SEC') and mailed to BLAC's stockholders. BLAC and OSR Holdings urge investors and other interested persons to read, when available, the BLAC proxy statement/prospectus, as well as other documents filed by BLAC with the SEC, because these documents will contain important information about the proposed business combination.

BLAC将准备代理声明/IPO（“BLAC代理声明/IPO”），将其提交给美国证券交易委员会（“SEC”），并邮寄给BLAC的股东。BLAC和OSR控股公司敦促投资者和其他感兴趣的人士阅读BLAC代理声明/IPO，以及BLAC向SEC提交的其他文件，因为这些文件将包含有关拟议业务组合的重要信息。

Such persons can also read BLAC's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and its registration statement on Form S-1 for its initial public offering, all as filed with the SEC for more information about BLAC and the security holdings of its officers and directors and their respective interests as security holders in the consummation of the transactions described herein.

这些人还可以阅读BLAC关于表格10-K的年度报告，关于表格10-Q的季度报告以及关于表格8-K的当前报告及其关于表格s-1的注册声明，以便首次公开发行，所有这些都向SEC提交了有关BLAC及其高级职员和董事的安全持有以及他们作为担保人的各自利益的更多信息，以完成本文所述的交易。

The BLAC proxy statement/prospectus, once available, and BLAC other reports can be obtained, without charge, at the SEC's web site (http://www.sec.gov)..

一旦可用，BLAC代理声明/IPO以及BLAC其他报告可以在SEC的网站上免费获得(http://www.sec.gov)..

Participants in the Solicitation

参与征集

BLAC, OSR Holdings, and their respective directors, executive officers and other members of their management and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of BLAC stockholders in connection with the proposed business combination. Investors and security holders may obtain more detailed information regarding the names, affiliations and interests of BLAC's directors and officers in its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on March 31, 2023, and its registration statement on Form S-1 for its initial public offering. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to BLAC's stockholders in connection with the proposed business combination will be set forth in the proxy statement/prospectus for the proposed business combination when available.

根据SEC规则，BLAC，OSR Holdings及其各自的董事，执行官及其管理层和员工的其他成员可能被视为与拟议的业务组合相关的BLAC股东代理人征集的参与者。投资者和担保人可以在截至2022年12月31日的财政年度10-K年度报告中获得有关BLAC董事和官员的姓名，从属关系和利益的更详细信息，该报告于3月31日提交给SEC 2023年及其在表格s-1上的首次公开发行注册声明。根据SEC规则，有关可能被视为参与向BLAC股东征集与拟议业务组合有关的代理人的信息将在拟议业务组合的代理声明/IPO中列出（如果有）。

Information concerning the interests of BLAC's and OSR Holdings' equity holders and participants in the solicitation, which may, in some cases, be different than those of BLAC's and OSR Holdings' equity holders generally, will be set forth in the proxy statement/prospectus relating to the proposed business combination when it becomes available..

有关BLAC和OSR控股股东的利益以及征求参与者的信息，在某些情况下，可能与BLAC和OSR控股股东的权益有所不同，将在代理声明/IPO中列出。当可用时，与拟议的业务组合有关。。

Forward Looking Statements

前瞻性声明

This press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of the businesses of BLAC and OSR Holdings may differ from their actual results and consequently, you should not rely on these forward-looking statements as predictions of future events.

本新闻稿包含1995年“私人证券诉讼改革法”的“安全港”规定含义内的“前瞻性声明”。BLAC和OSR持有业务的预期，估计和预测可能与其实际结果不同，因此，您不应依赖这些前瞻性陈述作为未来事件的预测。

Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believes,' 'predicts,' 'potential,' 'continue,' and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the satisfaction of the closing conditions to the proposed business combination, the timing of the completion of the proposed business combination and the future performance of OSR Holdings, including the anticipated impact of the proposed business combination on this performance.

诸如“期望”，“估计”，“项目”，“预算”，“预测”，“预期”，“打算”，“计划”，“可能”，“将会”，“可能”，“应该”，“应该”，“相信”，“预测”，“潜力”，“继续”，类似的表达旨在识别这种前瞻性陈述。这些前瞻性陈述包括但不限于对拟议业务组合的关闭条件的满意度，拟议业务组合完成的时间以及OSR持有的未来业绩，包括拟议业务组合的预期影响。在这个表现上。

These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of BLAC and OSR Holdings, and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreement with respect to the proposed business combination, (2) the outcome of any legal proceedings that may be instituted against the parties following the announcement of the proposed business combination and any definitive agreements with respect thereto; (3) the inability to complete the proposed business combination, includi.

这些前瞻性陈述涉及重大风险和不确定性，可能导致实际结果与预期结果大不相同。这些因素大多不在BLAC和OSR持有的控制范围之内，难以预测。可能导致此类差异的因素包括但不限于：（1）发生任何可能导致终止关于拟议业务组合的最终协议的事件，变更或其他情况，（2）拟议业务组合公布后可能对双方提起的任何法律诉讼的结果以及与之相关的任何明确协议；（3） 无法完成建议的业务组合，包括i。

No Offer or Solicitation

没有报价或征求

This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

本新闻稿不得构成对任何证券或拟议业务组合的代理，同意或授权的请求。本新闻稿也不构成出售或征求购买任何证券的报价，也不构成在任何国家或司法管辖区内出售证券，在这些报价，征求或销售之前是非法的根据任何此类管辖区的证券法注册或鉴定。

No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended..

除非通过符合经修订的1933年“证券法”第10条要求的IPO，否则不得发行证券。。

Contacts

联络

For OSR HoldingsSung Jae Yu, Chief Operating Officeralex.yu@osr-holdings.com

对于OSR HoldingsSung-Jae Yu，首席运营Officeralex.yu@osr-holdings.com

For BLACKuk Hyoun Hwang, CEO[email protected]

对于BLACKuk-Hyoun Hwang，首席执行官[电子邮件保护]

SOURCE Bellevue Life Sciences Acquisition Corp.

来源Bellevue生命科学收购公司。